搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FiercePharma
1 小时
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
BioPharma Dive
13 分钟
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
BioSpace
2 小时
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
The Pharma Letter
3 小时
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and ...
pharmaphorum
6 小时
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...
46 分钟
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower ...
18 小时
on MSN
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
Daily
7 小时
Pfizer RSV Vaccine Abrysvo gets USFDA ok for high-risk adults aged 18-59
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two ...
16 小时
Pfizer announces FDA approval of Abrysvo
Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...
19 小时
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...
18 小时
on MSN
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
Armed robbery in Revesby
8 小时
FDA Clears Pfizer RSV Vaccine for At-Risk Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈